loading
Annual Report and Accounts for the year ended 30 June 2018
Cookies This website uses cookies. Read our cookie policy for further details.
Sustaining Growth
Dechra Pharmaceuticals PLC
Dechra is an international specialist veterinary pharmaceuticals and related products business.
Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide.
Read More
Animal health globally is generally described as comprising two segments: Food producing Animal Products (FAP) and Companion Animal Products (CAP). FAP continues to show global growth due to an increased demand for high quality protein production, whereas CAP growth (a sector in which horses are generally included) is driven by the pet owners’ compassion for their animals, improved nutrition and a wider range of medical products and treatments.
2014
Commenced trading in
Italy
Acquired
PSPC
US bolt-on
2015
Canada and Poland
Genera
Entry into poultry vaccines
2016
Putney
Transformational US deal
Apex
Access to Australian CAP market
2017
Acquired 33% of
Medical Ethics
Access to novel product development
RxVet
Access to New Zealand
2018
AST Farma
Strengthens Dutch market position and provides direct-to-vet relationship
Le Vet
Adds to EU product portfolio
2013
16%
42%
9.6%
24.4%
40
50
13
24
2013 1,327
2018 4,680
£407.1m
2017: £359.3m
CER: +13.9%
AER: +13.3%
25.50p
2017: 21.44p
CER: +18.9%
AER: +18.9%
£99.2m
2017: £81.3m
CER: +24.0%
AER: +22.0%
£34.1m
2017: £33.2m
CER: +6.3%
AER: +2.7%
76.45p
2017: 64.33p
CER: +20.9%
AER: +18.8%
37.04p
2017: 27.93p
CER: +38.5%
AER: +32.6%
Watch Q&A
Dechra has delivered another strong set of financial results, from both existing business and acquisitions. We continue to invest both organically and through acquisitions to deliver enhanced shareholder value.
Richard CottonChief Financial Officer
STRATEGY IN ACTION:
Pipeline Delivery
Portfolio Focus
Geographical Expansion
Acquisition